Compare IOP Reduction

15 products »

close Created with Sketch.

Combigan

Allergan

Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated IOP in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

At-a-Glance
  • Mechanism of Action: Combigan is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Timolol maleate is a beta1 and beta2 adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.
  • Dosage: One drop in the affected eye(s), twice daily approximately 12 hours apart.

Details

FDA

Yes

CE Mark

Not specified

Active Ingredients

Brimonidine tartrate/timolol maleate

Application

Topical

Status

Prescription

Strength

0.2%/0.5%

From Your Peers

Post-Traumatic Iris Cyst Requiring Ethanol Irrigation

READ ARTICLE »

Show More

Company Information

Contact the company for additional information, availability, or pricing:

Allergan

allergan.com

5 Giralda Farms

Madison, NJ 07940